Acute Flaccid Myelitis: Cause, Diagnosis, and Management
Lancet 394:334-397, Murphy, O.C.,et al, 2021
Clinical Characteristics, Risk Factors, and Outcomes of POEMS Syndrome
Neurol 95:e268-e279, Keddie, S.,et al, 2020
Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis
JAMA 32:175-187, Brown, J.W.L.,et al, 2019
Diagnostic Tools for Immune Causes of Encephalitis
Clin Microbiol Infect 25:431-436, Lascano, A.M.,et al, 2019
Clinical Reasoning: A 49-year-old man with Progressive Numbness, Weakness, and Evidence of Leptomeningeal Enhancement
Neurol 90:e90-e93, Lovett, A.,et al, 2018
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
A 50-year-old Woman with SLE and a Tumefactive Lesion
Neurol 89:e140-e145, Choi, J.H.,et al, 2017
Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial
Lancet 390:2481-2489, Green, A.J.,et al, 2017
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Paraneoplastic Neurological Syndromes
Clin Exp Immunol 175:336-348, Leypoldt, F. & Wandinger, K.-P., 2014
Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013
Evidence-Based Guideline Update: Plasmapheresis in Neurologic Disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 76:294-300, Cortese,I.,et al, 2011
Rhombencephalitis A Series of 97 Patients
Medicine 90:256-261, Moragas, M.,et al, 2011
Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Curable Cause of Paraplegia: Spinal Dural Arteriovenous Fistulae
Stroke 39:2756-2759, Aghakhani,N.,et al, 2008
What Are the Prospects of Stem Cell Therapy for Neurology?
BMJ 337:1325-1327, Chandran,S., 2008
How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007
Spinal dural arteriovenous fistulas: a congestive myelopathy that initially mimics a peripheral nerve disorder
Brain 129:3150-3164, Jellema, K., et al, 2006
Effect of Mitoxantrone on MRI in Progressive MS, Results of the MIMS Trial
Neurol 65:690-695, Krapf,H.,et al, 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Interferon beta-1b in Secondary Progressive MS
Neurol 63:1779-1787,1768, Kappos,L.,et al, 2004
Interferon beta-1b in Secondary Progressive MS
Neurol 63:1788-1795,1768, The North American Study Group on Interferon beta-, 2004
Mitoxantrone for Multiple Sclerosis in Clinical Practice
Neurol 63(Suppl 6):S25-S27, Rizvi,S.A.,et al, 2004
Neurologic Manifestations in Primary Sjogren Syndrome: A Study of 82 Patients
Medicine 83:280-291, Delalande,S.,et al, 2004
The Use of Mitoxantrone (Novantrone) for the Treatment of Multiple Sclerosis
Neurol 61:1332-1338, Goodin,D.S.,et al, 2003
Euthanasia and Physician-Assisted Suicide Among Patients with Amyotrophic Lateral Sclerosis in the Netherlands
NEJM 346:1638-1644, Veldink,J.H.,et al, 2002
Benefit of Interferon B-1a on MSFC Progression in Secondary Progressive MS
Neurol 59:679-687, Cohen,J.A.,et al, 2002
Mitoxantrone in Progressive Multiple Sclerosis: A Placebo-Controlled, Double-Blind, Randomised, Multicentre Trial
Lancet 360:2018-2025, Hartung,H.,et al, 2002
Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1496-1504, Secondary Progressive Efficacy Clinical Trial of R, 2001
Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1505-1513, Li,D.K.B.,et al, 2001
The Effect of IFNB-1b on the Evolution of Enhancing Lesions in Secondary Progressive MS
Neurol 57:2185-2190, Brex,P.A.,et al, 2001
Relapses and Progression of Disability in Multiple Sclerosis
NEJM 343:1430-1438,1486, Confavreux,C.,et al, 2000
Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999
Retinocochleocerebral Vasculopathy
Medicine 77:12-40, Petty,G.W.,et al, 1998
Use of Corticosteroids in Multiple Sclerosis by Consultant Neurologists in the United Kingdom
JNNP 54:362-365, Tremlett,H.L.,et al, 1998
Placebo-Controlled Multicentre Randomised Trial of Interferon B-1b in Treatment of Secondary Progressive Multiple Sclerosis
Lancet 352:1491-1497,1486, European Study Group on Interferon B-1b in Seconda, 1998
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
Idiopathic Granulomatous Angiitis of the CNS Manifesting as Diffuse White Matter Disease
Neurol 49:1696-1699, Finelli,P.F.,et al, 1997
Palliative Care in Neurology
Neurol 46:870-872, 5981996., Bernat,J.L.,et al, 1996
Is Chronic Respiratory Failure in Neuromuscular Diseases Worth Treating
JNNP 61:1-3, Shneerson,J.M., 1996
Low-Dose Oral Methotrexate in Chronic Progressive Multiple Sclerosis:Analyses of Serial MRIs
Neurol 47:1153-1157, Goodkin,D.E.,et al, 1996
Low-Dose (7. 5mg) Oral Methotrexate Reduces the Rate of Progression in Chronic Progressive Multiple Sclerosis
Ann Nuerol 37:30-40, 51995., Goodkin,D.E.,et al, 1995
Are Magnetic Resonance Findings Pred of Clinical Outcome in Therapeutic Trials in MS? The Dilemma of Interferon-B
Ann Neurol 36:14-18, McDonald,W.I.,et al, 1994
Cladribine in Treatment of Chronic Progressive Multiple Sclerosis
Lancet 344:3-13, Sipe,J.C.,et al, 1994
Oral Megadose Methylprednisolone Therapy in a Pt with Chronic Progressive MS
Neurol 43:230, Gucuyener,K.,et al, 1993
Intermittent Cyclophosphamide Pulse Therapy in Progressive MS:NE Coop MS Trtm Grp
Neurol 43:910-918, Weiner,H.L.,et al, 1993
Clinicopath Conf
Acquired Demyelinating Neuropathy, ? CIDP, ? Motor Neuropathy with Multifocal Conduction Blocks, Cas, 41-1EJM 329:1182-1190,1993., 1993
Multifocal Demyelinating Motor Neuropathy:Cranial Nerve Involvement and Immunoglobulin Therapy
Neurol 42:506-509, Kaji,R.,et al, 1992